Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

122 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2024.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 79.5M shares of 122M outstanding shares and own 65.41% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), Frazier Life Sciences Management, L.P. (10.7M shares), VIKING GLOBAL INVESTORS LP (4.4M shares), Rubric Capital Management LP (4.21M shares), Point72 Asset Management, L.P. (4.15M shares), BlackRock, Inc. (3.93M shares), VANGUARD GROUP INC (3.51M shares), Vivo Capital, LLC (3.49M shares), Woodline Partners LP (3.21M shares), and MPM BIOIMPACT LLC (3.09M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.